Guide on biosimilars for healthcare professionals

EMA published the information guide on biosimilars for healthcare professionals in 15 additional EU languages. It now includes Bulgarian, Czech, Danish, Greek, Estonian, Finnish, Croatian, Hungarian, Lithuanian, Latvian, Maltese, Romanian, Slovak, Slovenian and Swedish. These educational materials on biosimilar, and link to the Q&A for patients, can be found on EMA’s webpage on biosimilar medicines…

Read More

Final guidance for treating neuroendocrine tumours (NETs)

Guidance issued by NICE (England) for treating neuroendocrine tumours (NETs) Final guidance recommending everolimus (Infinitor, Novartis) and sunitinib (Sutent, Pfizer) to treat neuroendocrine tumours (NETs). The drugs are recommended as an option for pancreatic NETs that cannot be operated on and have progressed. Everolimus is also recommended as an option for those with NETs of…

Read More

Draft guidance for chronic obstructive pulmonary disease – copd

NICE published draft guidance recommending roflumilast (Daxas, AstraZeneca) for chronic obstructive pulmonary disease (COPD). In 2012, NICE issued guidance that recommended roflumilast only if patients were taking it as part of a research study. New evidence since that guidance was published led to a positive recommendation for routine use. The company estimates that around 122,000…

Read More

The female factor in clinical trials

The female factor in clinical trials The European Parliament will discuss a non-binding report that calls for medicine labels to state whether the drugs were specifically tested in women and whether men and women may face different side effects. The report, drafted by the Spanish MEP Beatriz Becerra Basterrechea, asks the European Commission and EU…

Read More

Glaucoma drug may have potential as Alzheimer treatment

Drug used to treat glaucoma may have potential as Alzheimer treatment brimonidine, a drug routinely used to lower eye pressure in glaucoma patients, has been found to reduce the formation of amyloid proteins in the retina, in trials on rats, that are believed to be linked to Alzheimer’s. Amyloid plaques can be seen in the…

Read More

Draft guidance recommends pomalidomide (Imnovid, Celgene)

NICE has published draft guidance recommending pomalidomide (Imnovid, Celgene) for treating some people with multiple myeloma.  New data, including updated comparisons of pomalidomide with other treatments, was presented as part of this review. The committee concluded that pomalidomide could be recommended as a clinically and cost effective use of NHS resources in people whose disease…

Read More

WAKE UP Call: New EU Action Plan to fight Antimicrobial resistance!

Statement: WAKE UP Call: New EU Action Plan to fight Antimicrobial resistance! 18 November 2016 – on European Antibiotics Awareness Day (EAAD) the European Commission announced the launch of a new Action Plan to fight Antimicrobial Resistance in 2017. The aim is to reduce the over or misuse of antibiotics across all relevant sectors in…

Read More

Pancreatic cancer drug not recommended

Pancreatic cancer drug not recommended People with pancreatic cancer have very limited treatment options. HIgh costs of pegylated liposomal irinotecan means it is too expensive to recommend. said NICE (National Institute for Health and Care Excellence) as given in their draft guidance not recommending pegylated liposomal irinotecan also called nal-iri, Onivyde and made by Shire),…

Read More